Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

2023263 citationsJournal Articlegreen Open Access

Authors

Brendon L. Neuen · Brigham and Women's Hospital

Hiddo J.L. Heerspink · University of Groningen

Priya Vart · University of Groningen

Brian Claggett · Brigham and Women's Hospital

Robert A. Fletcher · UNSW Sydney

Clare Arnott · Royal Prince Alfred Hospital

Julianna de Oliveira Costa

Abstract

In patients with type 2 diabetes and at least moderately increased albuminuria, combination treatment of SGLT2i, GLP-1 RA, and ns-MRA has the potential to afford relevant gains in cardiovascular and kidney event-free and overall survival.

Topics & Keywords

Diabetes Treatment and Management Hormonal Regulation and Hypertension Apelin-related biomedical research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation

Volume 149, Issue 6, pp. 450-462

DOI: 10.1161/circulationaha.123.067584

Field-Weighted Citation Impact: 52.66